Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar ...

OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing, aiming to strengthen global supply ...

Witnesses at the April 8 hearing told legislators biosimilars save patients and taxpayers money, that pharmacy benefit ...

South Korea’s biosimilar drug developer Samsung Bioepis today presented the long-term safety data of Epysqli (eculizumab; ...

Learn more about the effects US pharmaceutical tariffs could have on European companies and their strategies for overcoming ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while ...

South Korea’s biosimilar drug developer Samsung Bioepis has announced that the company has entered into a license, ...

This adds to BioDlink's portfolio of international GMP approvals, following recent certifications in Brazil, Indonesia, Egypt ...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74 per ...

All SDRs and shares allocated have now been delivered to the counterparties, with a transfer of 7.5 million treasury shares ...

OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio ...